TRVI - Trevi Therapeutics, Inc.

QQQ $ 414.59 $ -8.60 (-2.03 %)

DIA $ 379.83 $ 1.96 (0.52 %)

SPY $ 494.96 $ -4.47 (-0.9 %)

TLT $ 89.15 $ 0.32 (0.36 %)

GLD $ 221.02 $ 0.69 (0.31 %)

Previous Close

$ 2.835

Open

$ 2.61

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 2.61 - $ 2.88

52 Week Range

$ 0.97 - $ 4.00

Volume

179,001

Average Volume

Market Cap

265.9M

Beta (5Y Monthly)

$ 0.69

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-20-2024	12-31-2023	10-K
2	11-09-2023	09-30-2023	10-Q
3	08-10-2023	06-30-2023	10-Q
4	05-11-2023	03-31-2023	10-Q
5	03-16-2023	12-31-2022	10-K
6	11-10-2022	09-30-2022	10-Q
7	08-11-2022	06-30-2022	10-Q
8	05-12-2022	03-31-2022	10-Q
9	03-17-2022	12-31-2021	10-K
10	11-10-2021	09-30-2021	10-Q
11	08-12-2021	06-30-2021	10-Q
12	05-13-2021	03-31-2021	10-Q
13	03-25-2021	12-31-2020	10-K
14	11-12-2020	09-30-2020	10-Q
15	08-13-2020	06-30-2020	10-Q
16	05-07-2020	03-31-2020	10-Q
17	03-16-2020	12-31-2019	10-K
18	11-14-2019	09-30-2019	10-Q
19	08-12-2019	06-30-2019	10-Q
20	06-14-2019	03-31-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Trevi Therapeutics to Present Phase 2 Resu...
04/09/2024 11:32:40

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Hadu...

Needham Reiterates Buy on Trevi Therapeuti...
04/09/2024 10:06:29

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.

Oppenheimer Maintains Outperform on Trevi ...
03/21/2024 12:56:35

Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and maintains $9 price target.

Needham Reiterates Buy on Trevi Therapeuti...
03/21/2024 10:53:03

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.

Trevi Therapeutics: Q4 Earnings Insights
03/20/2024 20:20:07

Trevi Therapeutics Q4 2023 GAAP EPS $(0.08...
03/20/2024 20:19:46

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(...

Earnings Scheduled For March 20, 2024
03/20/2024 09:32:15

Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per s...

Earnings Outlook For Trevi Therapeutics
03/19/2024 16:01:12

Trevi Therapeutics Gears Up for Data-Rich ...
01/04/2024 12:33:51

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Hadu...

Trevi Therapeutics Announces the Initiatio...
12/05/2023 12:33:34

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduv...

Trevi Therapeutics Q3 2023 Gaap EPS $(0.08...
11/09/2023 21:56:00

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(...

Earnings Scheduled For November 9, 2023
11/09/2023 11:52:51

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on re...

Trevi Therapeutics's Earnings: A Preview
11/08/2023 17:00:56

$trevi-therapeutics-has-initiated-its-phase-2a-river-trial-of-haduvio-in-refractory-chronic-cough-patients-topline-data-is-expected-in-the-second-half-of-2024$

Trevi Therapeutics Has Initiated Its Phase...
11/02/2023 11:46:05

Trevi Therapeutics Announces Results From ...
10/13/2023 12:37:00

Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatmentSafety data ov...

Needham Reiterates Buy on Trevi Therapeuti...
08/11/2023 09:30:24

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.

Trevi Therapeutics Q2 EPS $(0.07) Beats $(...
08/10/2023 20:14:33

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(...

Earnings Scheduled For August 10, 2023
08/10/2023 10:59:02

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share o...